Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis

Overview

Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of complications in liver disease. The purpose of this prospective, randomized trial is to determine whether metoprolol succinate can revert cardiac dysfunction secondary to cirrhosis (cirrhotic cardiomyopathy), and prevent complications (renal dysfunction, mortality). A total of 100 patients with cirrhotic cardiomyopathy will be randomized (Group R) to receive metoprolol succinate or placebo; other 25 patients without cirrhotic cardiomyopathy (Group F) will only be followed up without medication. All patients will be evaluated in the beginning and again after six months. The assessment protocol includes clinical evaluation, electrocardiogram, echocardiogram, laboratory analysis and life quality questionaire. The end points will be cardiac remodeling, electrophysiologic changes, sympathetic activity, laboratory issue changes, renal function, quality of life, and mortality.

Full Title of Study: “Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2013

Detailed Description

Cirrhotic cardiomyopathy (CMC) is defined as a chronic cardiac dysfunction in patients with cirrhosis. Moreover, it is characterized by an abnormal and blunted response to pathological or pharmacological stress in the absence of any other associated cardiac disease. The diagnostic criteria are: baseline increased cardiac output, attenuated myocardial contractile response to stress, diastolic dysfunction, and electrophysiological repolarization abnormalities. It is suspected that cardiac dysfunction in cirrhosis contribute to the onset of complications in liver disease. We will investigate the effect of metoprolol succinate in the reversal of cardiac dysfunction and prevention of complications of cirrhosis in patients with cirrhotic cardiomyopathy. Furthermore, we want to study the influence of presence of CMC in the evolution of cirrhotic patients. The study will be prospective, randomized, double-blind, and placebo-controlled. The sample consists of 125 patients aged between 18 and 60 years old diagnosed with severe liver cirrhosis (Child B or C or MELD score above 10) with cirrhotic cardiomyopathy or not. Of these, 100 patients with cirrhotic cardiomyopathy will be randomized into two groups: group R1 (metoprolol succinate) and group R2 (placebo). Group F will consist of cirrhotic patients without cardiomyopathy and will not receive medication. Patients will be evaluated by clinical examination, resting electrocardiogram, 24-hour Holter, stress echocardiography and laboratory (brain natriuretic peptide (BNP), catecholamines, plasma renin activity, and troponin) at inclusion and after six months. The end points are: 1) Reversal of cardiac dysfunction in patients with cirrhotic cardiomyopathy, 2) Development of hepatorenal syndrome, 3) Reversal of the electrophysiologic abnormalities, 4)Changes in laboratory tests, and 5) Mortality.

Interventions

  • Drug: Metoprolol succinate
  • Drug: placebo

Arms, Groups and Cohorts

  • Active Comparator: Metoprolol succinate
    • Metoprolol succinate
  • Placebo Comparator: Placebo
    • Placebo
  • No Intervention: Follow up
    • Group without cirrhotic cardiomyopathy, only follow up without randomization.

Clinical Trial Outcome Measures

Primary Measures

  • Improvement of systolic function
    • Time Frame: six months
    • Systolic functional reserve is measured by aortic velocity time integral in echocardiographic at rest and stress with dobutamine.

Secondary Measures

  • Improvement in left ventricular diastolic function
    • Time Frame: six months
  • Renal function
    • Time Frame: From randomization until six months
  • Serum level of BNP, catecholamines, plasmatic renin activity
    • Time Frame: Six months
  • Mortality
    • Time Frame: From randomization until six months of follow up
  • Quality of life
    • Time Frame: Six months
  • Electrophysiologic modifications
    • Time Frame: Six months
    • QT prolongation R-R variability

Participating in This Clinical Trial

Inclusion Criteria

  • more than 18 years old. – must have signed the written informed consent. – nonalcoholic cirrhosis. Exclusion Criteria:

  • Betablockers intolerance; – Diagnosis of other cardiomyopathy – Chronicle renal disease (Creatinine > 2.5) – Heavy alcohol intake history – Presence of other disease with possible cardiac implication (infiltrative or storage disease)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Sao Paulo
  • Collaborator
    • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Provider of Information About this Clinical Study
    • Principal Investigator: Fernando Bacal, MD; PhD – University of Sao Paulo
  • Overall Official(s)
    • Fernando Bacal, MD, PhD, Principal Investigator, University of Sao Paulo School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.